No out of pocket costs for eligible patients
Eligible patients can receive financial support when coverage fails. If insurance is denied or a patient is uninsured, the Epilepsy Partnership Program provides coverage.
Access to comprehensive testing
Patients gain access to GeneDx exome testing, offering a more complete view of genetic variation and helping identify conditions with greater clarity.
Advances future care
De-identified genetic data generated through this program supports research and the development of future therapies, contributing to improved care for individuals with epilepsy.
Exome sequencing is recommended as a first-line test for individuals with epilepsy.
Many patients are still receiving narrow tests, such as multi-gene panels, many of which do not include analysis of all seizure-related genes. In fact, 57% of seizure-related genes are not included on many commercially available epilepsy panels.2
To help pediatric patients with epilepsy access guideline-backed exome testing, GeneDx has teamed up with leading biopharma partners to offer the Epilepsy Partnership Program. Through this program, denial of an insurance claim or lack of insurance coverage does not impact eligible patients’ ability to access recommended testing.
Who is eligible?
Patients must meet all six criteria:
- Reside in the United States.
- Are under 18 years of age.
- Experienced their first unprovoked seizure before 8 years of age.
- Have not had prior genetic testing performed by a clinical laboratory confirming a diagnosis of a neurodevelopmental disorder.
- Have an ordering provider authorized under applicable law to order genetic testing in the United States.
- Have provided consent to the mandatory data-sharing practices stated in the test requisition form (TRF)/provider attestation on the portal.
How does the program work?
The testing works like any other GeneDx exome test order, with a few main differences:
Eligibility
Eligibility criteria must be met.
Ordering
For portal orders, provide the program code (ESEPL) after adding the exome test to your cart. For paper TRF orders, the Epilepsy Partnership Program-specific TRF must be used.
Data Sharing
The ordering provider must confirm that they have consented the patient to the program’s mandatory data practices.
Billing
Should the patient’s insurance provider deny coverage of the exome test, or if the patient is uninsured, our pharma partners will cover the cost of testing.
Helpful resources
Test Requisition Form
Use the Epilepsy Partnership Program–specific test requisition form to ensure your order is processed correctly and eligibility is applied.
Speak to a representative
Learn more about genomic sequencing as the first step to diagnosis by reaching out to our team for support.
Our practices aim to protect patients while accelerating the development of epilepsy therapeutics. The Epilepsy Partnership Program is supported by biopharma industry partners who receive the following information:
‍
- De-identified patient data, such as reportable variants, for patients tested through the program.
- Contact information for providers ordering testing through the program.
‍
This data plays a critical role in developing novel therapies for patients with epilepsy. Together, we can help shape the future of personalized medicine.
‍
GeneDx will never share any personally identifiable patient information or raw sequencing data with biopharma industry partners.
Ready to bring genomics into your practice?
We’re here to support every step.